The Immune Escape: Sana Biotechnology's 14-Month Data Brings a Functional Cure for Type 1 Diabetes Into View

There is a phrase that researchers in the type 1 diabetes field have been careful not to use for decades. "Functional cure" carries the weight of too many failed promises, too many early-stage results that looked transformative in a petri dish and collapsed in the clinic. So when Sana Biotechnology published 14-month follow-up data from a first-in-human study on March 13, 2026, showing that transplanted insulin-producing cells are still alive, still functioning, and still evading the immune system without any immunosuppression, the careful language in the press release was notable. The company's own principal investigator used the phrase anyway.

Per-Ola Carlsson, the senior physician and professor at Uppsala University Hospital who led the investigator-sponsored study, said the results "suggest that the hypoimmune technology has the potential to enable a functional cure for type 1 diabetes without immunosuppression." That is not a phrase scientists deploy casually. It is worth understanding why he said it, and what the data actually show.

What the Study Did and What It Found

The study evaluated UP421, a donor-derived primary islet cell therapy engineered with Sana's hypoimmune platform, known as HIP technology. The core idea behind HIP is straightforward in concept and extraordinarily difficult in execution: modify donor cells so that the recipient's immune system does not recognize them as foreign. In type 1 diabetes, this problem is compounded by the fact that the immune system is not just rejecting foreign tissue. It is also actively attacking the patient's own insulin-producing beta cells, the same autoimmune process that caused the disease in the first place. A therapy that only solves the allogeneic rejection problem would still face the autoimmune attack. HIP is designed to solve both.

The 14-month data, presented at the Advanced Technologies and Treatments for Diabetes conference in March 2026, show that the transplanted cells are still producing insulin. C-peptide, a biomarker of endogenous insulin production, remains detectable in the patient's circulation and rises in response to a meal tolerance test. PET-MRI scanning at 52 weeks confirmed the presence of islet cells at the transplant site, which was a forearm muscle. No safety issues have been identified. Between months 12 and 14, the patient achieved tighter glycemic control, and the improved insulin secretion at month 14 was higher than at months 9 and 12, a finding the investigators attribute to the positive effect of better glucose management on beta cell function.

This last point deserves emphasis. The cells are not just surviving. They appear to be responding dynamically to the patient's metabolic environment, functioning more effectively as glycemic control improves. That is not the behavior of cells in a slow decline. It is the behavior of cells that have found a stable home.

Why This Is Different From Everything That Came Before

Islet cell transplantation is not a new idea. The Edmonton Protocol, developed in the early 2000s, demonstrated that transplanting donor islet cells into patients with type 1 diabetes could restore insulin independence. The problem was immunosuppression. The drugs required to prevent rejection were toxic, increased infection risk, and were themselves damaging to the transplanted cells. Most patients eventually lost graft function and returned to insulin dependence. The treatment traded one chronic disease management burden for another.

What Sana's HIP technology attempts to do is remove that trade-off entirely. By engineering the donor cells to express specific proteins that signal "self" to the immune system, the therapy aims to make immunosuppression unnecessary. The 14-month data from a single patient represent the first sustained human evidence that this approach can work. One patient is not a clinical trial. The investigators are explicit about this. The study used a low dose of HIP-modified primary islets, not intended to demonstrate glycemic improvement, but to establish safety and proof-of-concept for immune evasion. What it has shown, over more than a year, is that the cells survive, function, and continue to evade immune detection without any pharmacological assistance.

The Path to a Scalable Therapy

The more commercially significant development is what Sana plans to do with this proof-of-concept. The company is advancing SC451, a HIP-modified stem cell-derived islet therapy, which addresses the fundamental scalability problem with primary islet transplantation. Donor-derived islets are scarce. There are not enough deceased donors to treat the roughly 1.6 million Americans with type 1 diabetes, let alone the global population. A stem cell-derived approach, if it can replicate the immune evasion properties demonstrated with UP421, would remove that constraint entirely.

Sana expects to file an investigational new drug application for SC451 and initiate a Phase 1 trial as early as 2026. The company has already generated significant foundational intellectual property in the HIP platform and has published preclinical data across multiple cell types demonstrating immune evasion in both the adaptive and innate arms of the immune system. The Uppsala study provides the human validation that preclinical data alone cannot supply.

The Biogen partnership that Sana announced in 2024 adds commercial infrastructure to the scientific story. Sana retains rights in the United States, Canada, and Mexico, while Biogen holds commercialization rights elsewhere. For Biogen, which has been navigating a difficult period following the controversies surrounding its Alzheimer's program, a successful rare disease launch in a high-profile indication like type 1 diabetes would represent a meaningful strategic reorientation.

What the Data Cannot Yet Tell Us

The honest accounting of where this program stands requires acknowledging what 14 months of data from a single patient cannot establish. The dose used in the Uppsala study was intentionally low, designed to test safety and immune evasion rather than to achieve insulin independence. The patient has not stopped using exogenous insulin. The study was not designed to show that. What it was designed to show is that HIP-modified cells can survive in a human being without immunosuppression for more than a year, and that they continue to produce insulin in response to physiological signals. On those specific questions, the data are encouraging.

The harder questions, whether higher doses can achieve meaningful glycemic improvement, whether the effect is durable over five or ten years, whether SC451 can replicate the immune evasion properties of primary islets at scale, will require the Phase 1 trial and the studies that follow it. The field has been here before with cell therapy programs that showed early promise and encountered unexpected obstacles in larger, more rigorous studies.

A Moment Worth Marking

None of that caution diminishes what the 14-month data represent. The immunosuppression requirement has been the central obstacle to islet transplantation as a viable treatment for type 1 diabetes for more than two decades. Every serious attempt to solve it has either failed in humans or has not yet been tested in humans. Sana's HIP platform has now demonstrated, in a living person, that donor-derived insulin-producing cells can survive and function for more than a year without triggering immune rejection, in a disease where the immune system is specifically primed to destroy those cells.

That is a meaningful scientific milestone, even if it is not yet a therapy. The principal investigator's careful use of the phrase "functional cure" reflects a genuine assessment of what the technology could become, not a marketing claim about what it already is. For the 1.6 million Americans managing type 1 diabetes with insulin pumps, continuous glucose monitors, and the constant cognitive load of a disease that never takes a day off, the distinction between "could become" and "already is" matters enormously. But so does the direction of travel. And for the first time in a long time, the direction is genuinely promising.